Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

M, Kosiborod; CSP, Lam; S, Kohsaka; DJ, Kim; A, Karasik; J, Shaw; N, Tangri; SY, Goh; M, Thuresson; H, Chen; F, Surmont; N, Hammar; P, Fenici

doi:10.1016/j.jacc.2018.03.009

Public

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

Shared by NobleBlocks on Mar 11, 2018 • 12:00 AM UTC

Authors:

Kosiborod M

Lam CSP

Kohsaka S

Abstract

Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, b...

Subject

Diabetes mellitus

Death

Heart Failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!